Crimson Cup Customer Angie's Sugar Buzz Bakery Named Best Business of the Year by Sandwich Area Chamber of Commerce
SANDWICH, Ill., May 15, 2025 /PRNewswire/ -- In a sweet victory for both baked goods and exceptional coffee, Angie's Sugar Buzz Bakery — a customer of Crimson Cup Coffee & Tea — has been named Best Business of the Year by the Sandwich Area Chamber of Commerce.
Award Cements Reputation for Sweet Success
The recognition celebrates owner Angie Davis's commitment to building a welcoming, community-driven destination for high-quality bakery treats and award-winning specialty coffee.
"I was deeply honored to receive the Best Business of the Year award," Davis said. "I truly love this community and can't imagine being anywhere else. Thank you so very much to all who voted for me. I hope to be a staple in this community for many years to come, making sweet memories!"
This is just the latest in a string of honors for Angie's Sugar Buzz, which has also been recognized with the Illinois Made designation, voted Best Bakery and Best Coffee by FOX, and featured on Chicago's Best.
Coffee Expansion Fueled by Crimson Cup Partnership
Davis's Sugar Buzz Bakery opened in January 2014, then expanded its offerings in 2021 to include handcrafted coffee and espresso drinks, roasted by Crimson Cup Coffee & Tea. A fellow coffee shop owner referred Davis to Crimson Cup, an award-winning roaster based in Columbus, Ohio. Its 7 Steps to Success program gave Angie the hands-on training, coffee knowledge and business coaching she needed to elevate her coffee program.
"I always wanted something like Central Perk from 'Friends' — a local place that brings the community together," she said. "Crimson Cup helped me bring that vision to life."
"I couldn't have done it on my own. I tried. The support is amazing," she added. "They've helped with everything from recipes and training to price margins and equipment."
A Local Favorite with Deep Community Roots
Angie's Sugar Buzz is known for its warm atmosphere, rustic decor and standout menu of donuts, cookies, muffins and cakes. "We invite the customers in with a warm smile and hope that they stay awhile," said Davis. "You can work or play here — all while indulging in a sweet treat."
Active in the Sandwich community, Angie's Sugar Buzz supports local schools, churches and nonprofits, and regularly participates in chamber events and fundraisers. "Our community supports us, and I believe it's important to give back," she said.
As she reflects on 11 years in business, Davis says the best part has been the people. "The flexibility is great, but it's the people we've met along the way who make it all worth it."
Advice for Future Owners: 'Be in It to Win It'
Her advice for other small business owners? "Be in it to win it! Take on the challenges and stay positive." And for anyone considering Crimson Cup as a coffee partner: "It's a no-brainer. Do it. Listen to their advice and get at it."
About Crimson Cup Coffee & Tea
Founded in 1991, Crimson Cup Coffee & Tea is a leader in the specialty coffee industry, recognized for award-winning quality and commitment to sustainability. The company's accolades include multiple Good Food Awards, the 2025 Golden Bean World Series Championship and Roast magazine's 2016 Macro Roaster of the Year.
Through its Friend2Farmer initiatives, Crimson Cup supports coffee-growing communities with sustainable, mutually beneficial partnerships. Its 7 Steps to Success program empowers entrepreneurs to open independent coffee shops by providing a detailed coffee shop business plan template, hands-on training, award-winning coffee and ongoing consulting.
Crimson Cup coffee is served in over 700 independent coffeehouses, grocers, universities, restaurants, and food service locations across 36 states and Bangladesh. The company also operates its own Crimson Cup and CRIMSON coffeehouses in Ohio. To learn more, visit crimsoncup.com.
View original content to download multimedia:https://www.prnewswire.com/news-releases/crimson-cup-customer-angies-sugar-buzz-bakery-named-best-business-of-the-year-by-sandwich-area-chamber-of-commerce-302456658.html
SOURCE Crimson Cup Coffee & Tea
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
17 hours ago
- Yahoo
FibroBiologics Appoints Jason D. Davis, CPA, as Chief Financial Officer
Seasoned finance executive brings over 20 years of public company and capital markets experience to support clinical-stage growth HOUSTON, June 09, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) ('FibroBiologics'), a clinical-stage biotechnology company with 275+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced the appointment of Jason D. Davis, CPA, as Chief Financial Officer, effective immediately. Mr. Davis brings extensive experience in corporate finance, capital markets, and SEC reporting, with a proven track record of successfully leading companies through critical growth phases, including IPOs and capital raising initiatives. His appointment comes as FibroBiologics advances toward its Phase 1/2 clinical trial for diabetic foot ulcers in the second half of 2025 and continues to expand its fibroblast-based therapeutic platform. 'Jason brings exactly the kind of experience and leadership we need at this pivotal moment. His deep understanding of public company operations and capital markets isn't just helpful — it's a force multiplier as we move our lead program into the clinic. He knows how to raise capital in a complex biotech environment, and that makes him a critical part of our mission to drive long-term innovation and deliver exceptional value to shareholders,' commented Pete O'Heeron, FibroBiologics' Founder, Chairman and Chief Executive Officer. Mr. Davis added, 'FibroBiologics, with its fibroblast-based platform, strong intellectual property portfolio, and well-defined clinical strategy, offers a truly differentiated approach to the development of therapeutics and potential cures for chronic diseases, and has all the elements of a high-growth, high-impact enterprise. I'm excited to bring my experience in public company finance to the table as we execute, scale, and deliver meaningful value — not just for shareholders, but for patients around the world.' Mr. Davis most recently served as Chief Financial Officer of Virax Biolabs, where he helped navigate the company through its successful IPO in July 2022. During his tenure, he led multiple capital raises with favorable terms, managed all periodic reports and other filings with the SEC, and implemented public company governance best practices. Prior to Virax, Mr. Davis served in various finance roles for several public companies, including HyperDynamics Corp, where he increased the company's market cap from $20 million to over $700 million and raised over $200 million in multiple transactions from U.S. and European capital markets. He received his B.B.A. in Accounting from the University of Houston and is a CPA certified in Texas. For more information, please visit FibroBiologics' website or email FibroBiologics at info@ Cautionary Statement Regarding Forward-Looking Statements This communication contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. Forward-looking statements include information concerning plans for, and the timing of, clinical trials, and the role to be played by, and impact of, the Chief Financial Officer. These forward-looking statements are based on FibroBiologics' management's current expectations, estimates, projections and beliefs, as well as a number of assumptions concerning future events. These forward-looking statements are not guarantees of future performance, conditions or results, and involve a number of known and unknown risks, uncertainties, assumptions and other important factors, many of which are outside FibroBiologics' management's control, that could cause actual results to differ materially from the results discussed in the forward-looking statements, including those set forth under the caption "Risk Factors" and elsewhere in FibroBiologics' annual, quarterly and current reports (i.e., Form 10-K, Form 10-Q and Form 8-K) as filed or furnished with the SEC and any subsequent public filings. Copies are available on the SEC's website, These risks, uncertainties, assumptions and other important factors include, but are not limited to: (a) risks related to FibroBiologics' liquidity and its ability to maintain capital resources sufficient to conduct its business; (b) expectations regarding the initiation, progress and expected results of our R&D efforts and preclinical studies; (c) the unpredictable relationship between R&D and preclinical results and clinical study results; and (d) the ability of FibroBiologics to successfully prosecute its patent applications. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and FibroBiologics assumes no obligation and, except as required by law, does not intend to update, or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. FibroBiologics gives no assurance that it will achieve its expectations. About FibroBiologics Based in Houston, FibroBiologics is a clinical-stage biotechnology company developing a pipeline of treatments and seeking potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. FibroBiologics holds 275+ US and internationally issued patents/patents pending across various clinical pathways, including wound healing, multiple sclerosis, disc degeneration, psoriasis, orthopedics, human longevity, and cancer. FibroBiologics represents the next generation of medical advancement in cell therapy and tissue regeneration. For more information, visit General Inquiries:info@ Investor Relations:Nic JohnsonRusso Partners(212) 845-4242fibrobiologicsIR@ Media Contact:Liz PhillipsRusso Partners(347)
Bloomberg
a day ago
- Bloomberg
Starbucks Joins China Price War With Discounts for Tea Drinks
Starbucks Corp. on Monday announced price cuts for a slew of its tea-based beverages at its stores across China, as the American coffee chain takes a more aggressive approach to revive sales at its second-biggest market. Starbucks will reduce prices by 5 yuan (70 cents) on average across more than a dozen Frappuccino, iced tea and tea latte options in its latest campaign to appeal to Chinese consumers for non-coffee offerings during summer, according to a statement posted on the company's official account on Chinese social media WeChat on Monday .
Yahoo
a day ago
- Yahoo
Salary cap impact of Jaguars releasing Gabe Davis with post-June 1st designation
The Jacksonville Jaguars announced on Wednesday that they were releasing wide receiver Gabe Davis, and on Thursday afternoon, that move became official. Davis was waived with failed physical and post-June 1st designations, according to Aaron Wilson. As it pertains to the post-June 1st designations, that does come with some noteworthy salary cap ramifications for both 2025 and 2026. Advertisement Last offseason, Davis signed a three-year, $39 million deal with $24 million guaranteed. By releasing Davis at this point, the Jaguars are taking on a hefty amount of dead cap--which are dollars that have been paid to the player but not yet accounted for on the salary cap--of $20.3 million. The decision that the Jaguars had was to either absorb that full $20.3 million in dead cap on the 2025 salary cap, but be out from under Davis' deal in 2026, or use the post-June 1st designation to spread the dead cap hit out. By choosing the latter, Davis will leave behind a dead cap hit of $5.7 million in 2025, but also a $14.6 million dead cap hit in 2026, according to Over the Cap. So even though Davis will be playing elsewhere, he will still be on the Jaguars' salary cap books for each of those amounts over the next two seasons. This article originally appeared on Jaguars Wire: Salary cap impact of releasing Gabe Davis with post-June 1st designation
